Interpace Biosciences, Inc. (IDXG)
USD 0.64
(-12.86%)
USD 0.64
(-12.86%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.83 Million USD | 201.48% |
| 2022 | -2.26 Million USD | 53.79% |
| 2021 | -1.32 Million USD | 62.17% |
| 2020 | -20.09 Million USD | -7.68% |
| 2019 | -21.71 Million USD | -183.61% |
| 2018 | -8.56 Million USD | 34.24% |
| 2017 | -9 Million USD | 3.45% |
| 2016 | -2.15 Million USD | 56.97% |
| 2015 | -35.47 Million USD | -186.12% |
| 2014 | -13.34 Million USD | -217.71% |
| 2013 | -212 Thousand USD | -111.3% |
| 2012 | 725 Thousand USD | 1637.64% |
| 2011 | -1.67 Million USD | 33.44% |
| 2010 | -3.07 Million USD | 45.47% |
| 2009 | -14.16 Million USD | 84.4% |
| 2008 | -28.97 Million USD | -281.17% |
| 2007 | -8.67 Million USD | -156.59% |
| 2006 | 16.41 Million USD | 152.71% |
| 2005 | -5.38 Million USD | -163.26% |
| 2004 | 41.88 Million USD | 45.59% |
| 2003 | 28.07 Million USD | 173.1% |
| 2002 | -39.58 Million USD | -345.69% |
| 2001 | 17.69 Million USD | -59.51% |
| 2000 | 42.95 Million USD | 160.88% |
| 1999 | 16.9 Million USD | 94.67% |
| 1998 | 10 Million USD | -16.67% |
| 1997 | 3 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.03 Million USD | -5.74% |
| 2024 Q2 | 2.44 Million USD | 136.46% |
| 2024 Q3 | 1.59 Million USD | -34.72% |
| 2023 Q4 | 1.36 Million USD | 508.93% |
| 2023 Q2 | 1.01 Million USD | -3.24% |
| 2023 Q3 | 224 Thousand USD | -77.95% |
| 2023 Q1 | 1.05 Million USD | 243.64% |
| 2023 FY | - USD | 201.48% |
| 2022 Q4 | -731 Thousand USD | -101.93% |
| 2022 FY | - USD | 53.79% |
| 2022 Q1 | -1 Million USD | 65.93% |
| 2022 Q2 | -3.12 Million USD | -209.62% |
| 2022 Q3 | -362 Thousand USD | 88.4% |
| 2021 Q1 | -1.21 Million USD | 83.35% |
| 2021 FY | - USD | 62.17% |
| 2021 Q3 | -2.18 Million USD | -125.83% |
| 2021 Q2 | -968 Thousand USD | 20.53% |
| 2021 Q4 | -2.95 Million USD | -35.36% |
| 2020 Q2 | -3.94 Million USD | 18.47% |
| 2020 Q4 | -7.31 Million USD | -64.22% |
| 2020 Q3 | -4.45 Million USD | -12.93% |
| 2020 Q1 | -4.83 Million USD | 49.79% |
| 2020 FY | - USD | -7.68% |
| 2019 FY | - USD | -183.61% |
| 2019 Q1 | -2.41 Million USD | -36.6% |
| 2019 Q2 | -3.08 Million USD | -27.58% |
| 2019 Q3 | -5.18 Million USD | -68.26% |
| 2019 Q4 | -9.63 Million USD | -85.92% |
| 2018 Q2 | -1.01 Million USD | 55.74% |
| 2018 FY | - USD | 34.24% |
| 2018 Q4 | -1.76 Million USD | 6.11% |
| 2018 Q3 | -1.88 Million USD | -86.44% |
| 2018 Q1 | -2.28 Million USD | 43.29% |
| 2017 FY | - USD | 3.45% |
| 2017 Q4 | -4.02 Million USD | -60.13% |
| 2017 Q3 | -2.51 Million USD | 4.85% |
| 2017 Q1 | -1.14 Million USD | 62.97% |
| 2017 Q2 | -2.64 Million USD | -131.26% |
| 2016 Q2 | -1.75 Million USD | 30.71% |
| 2016 Q1 | -2.53 Million USD | 90.37% |
| 2016 Q4 | -3.08 Million USD | 3.47% |
| 2016 FY | - USD | 56.97% |
| 2016 Q3 | -3.19 Million USD | -81.74% |
| 2015 Q4 | -26.34 Million USD | -856.68% |
| 2015 FY | - USD | -186.12% |
| 2015 Q1 | -1.77 Million USD | 58.1% |
| 2015 Q2 | -4.7 Million USD | -165.26% |
| 2015 Q3 | -2.75 Million USD | 41.44% |
| 2014 FY | - USD | -217.71% |
| 2014 Q3 | -3.73 Million USD | -74.15% |
| 2014 Q4 | -4.23 Million USD | -13.4% |
| 2014 Q2 | -2.14 Million USD | -106.06% |
| 2014 Q1 | -1.04 Million USD | 66.75% |
| 2013 Q3 | -1.7 Million USD | -205.91% |
| 2013 Q1 | 2.54 Million USD | -89.63% |
| 2013 Q2 | -558 Thousand USD | -121.96% |
| 2013 Q4 | -3.12 Million USD | -83.25% |
| 2013 FY | - USD | -111.3% |
| 2012 Q2 | -301 Thousand USD | -207.12% |
| 2012 Q1 | 281 Thousand USD | 114.36% |
| 2012 Q4 | 24.5 Million USD | 9453.82% |
| 2012 FY | - USD | 1637.64% |
| 2012 Q3 | -262 Thousand USD | 12.96% |
| 2011 Q3 | 860 Thousand USD | 561.54% |
| 2011 Q2 | 130 Thousand USD | 119.23% |
| 2011 FY | - USD | 33.44% |
| 2011 Q4 | -1.95 Million USD | -327.56% |
| 2011 Q1 | -676 Thousand USD | 63.38% |
| 2010 Q4 | -1.84 Million USD | -338.19% |
| 2010 Q1 | -1.33 Million USD | -111.96% |
| 2010 FY | - USD | 45.47% |
| 2010 Q2 | -408 Thousand USD | 69.37% |
| 2010 Q3 | 775 Thousand USD | 289.95% |
| 2009 Q1 | -4.88 Million USD | 55.45% |
| 2009 Q2 | -3.92 Million USD | 19.68% |
| 2009 FY | - USD | 84.4% |
| 2009 Q3 | -3.95 Million USD | -0.92% |
| 2009 Q4 | 11.14 Million USD | 381.46% |
| 2008 Q1 | -1.5 Million USD | -138.12% |
| 2008 Q4 | -10.96 Million USD | -19.51% |
| 2008 FY | - USD | -281.17% |
| 2008 Q3 | -9.17 Million USD | -24.45% |
| 2008 Q2 | -7.37 Million USD | -390.03% |
| 2007 Q2 | -2.49 Million USD | -15.99% |
| 2007 Q1 | -2.15 Million USD | -167.83% |
| 2007 FY | - USD | -156.59% |
| 2007 Q4 | 3.94 Million USD | 174.0% |
| 2007 Q3 | -5.33 Million USD | -113.67% |
| 2006 Q3 | 217 Thousand USD | -85.08% |
| 2006 Q4 | 3.17 Million USD | 1361.29% |
| 2006 Q2 | 1.45 Million USD | -82.66% |
| 2006 Q1 | 8.38 Million USD | 146.25% |
| 2006 FY | - USD | 152.71% |
| 2005 Q1 | 42 Thousand USD | -99.57% |
| 2005 Q2 | -914 Thousand USD | -2276.19% |
| 2005 Q3 | -4.01 Million USD | -338.95% |
| 2005 Q4 | -18.13 Million USD | -351.99% |
| 2005 FY | - USD | -163.26% |
| 2004 Q1 | 11 Million USD | 11.1% |
| 2004 Q3 | 10.16 Million USD | 9.05% |
| 2004 FY | - USD | 45.59% |
| 2004 Q4 | 9.83 Million USD | -3.24% |
| 2004 Q2 | 9.32 Million USD | -15.29% |
| 2003 FY | - USD | 173.1% |
| 2003 Q2 | 5.94 Million USD | 224.09% |
| 2003 Q4 | 9.82 Million USD | 20.56% |
| 2003 Q3 | 8.46 Million USD | 43.69% |
| 2003 Q1 | 2.3 Million USD | 188.42% |
| 2002 Q4 | -3.97 Million USD | 89.22% |
| 2002 Q1 | -2.96 Million USD | -116.82% |
| 2002 Q2 | -13.17 Million USD | -250.89% |
| 2002 Q3 | -19.02 Million USD | -36.77% |
| 2002 FY | - USD | -345.69% |
| 2001 Q2 | 7.39 Million USD | -63.08% |
| 2001 Q4 | 20.79 Million USD | 178.49% |
| 2001 Q1 | 17.72 Million USD | 1.77% |
| 2001 Q3 | -28.21 Million USD | -599.04% |
| 2001 FY | - USD | -59.51% |
| 2000 FY | - USD | 160.88% |
| 2000 Q4 | 17.51 Million USD | 163.61% |
| 2000 Q3 | 7.89 Million USD | -27.34% |
| 2000 Q2 | 8.38 Million USD | -3.97% |
| 2000 Q1 | 9.15 Million USD | 34.43% |
| 1999 Q1 | 4.42 Million USD | 200.0% |
| 1999 Q2 | 4.5 Million USD | 66.67% |
| 1999 Q3 | 3.3 Million USD | -54.0% |
| 1999 FY | - USD | 94.67% |
| 1999 Q4 | 6.1 Million USD | 173.91% |
| 1998 Q2 | 1.6 Million USD | -90.91% |
| 1998 FY | - USD | -16.67% |
| 1998 Q3 | 1.8 Million USD | 0.0% |
| 1998 Q4 | 1.7 Million USD | 25.0% |
| 1998 Q1 | 4.9 Million USD | 123.53% |
| 1997 Q4 | -37.4 Million USD | -351.01% |
| 1997 Q2 | 14.9 Million USD | 49.0% |
| 1997 Q1 | 10 Million USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q3 | 14.9 Million USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| American Bio Medica Corporation | -1.16 Million USD | 429.923% |
| Arrayit Corporation | -3.07 Million USD | 224.679% |
| Atlantic International Corp. | -5.38 Million USD | 171.193% |
| Biocept, Inc. | -30.24 Million USD | 112.688% |
| Bioqual, Inc. | 3.03 Million USD | -26.54% |
| CardioGenics Holdings Inc | -757.37 Thousand USD | 606.618% |
| DermTech, Inc. | -97.89 Million USD | 103.92% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 2.91 Billion USD | 99.868% |
| HTG Molecular Diagnostics, Inc. | -20.24 Million USD | 118.955% |
| iMD Companies, Inc. | -154.65 Thousand USD | 2580.942% |
| IDenta Corp. | 71.58 Thousand USD | -5259.912% |
| Integrative Health Technologies, Inc. | 38.69 Thousand USD | -9817.291% |
| InVitro International | 6680.00 USD | -57340.12% |
| Lumos Diagnostics Holdings Limited | -5.43 Million USD | 170.585% |
| Many Bright Ideas Technologies Inc. | -12.13 Thousand USD | 31721.889% |
| Medical Imaging Corp. | -896.74 Thousand USD | 527.882% |
| NovelStem International Corp. | -3.78 Million USD | 201.352% |
| Optigenex Inc. | -1.18 Million USD | 423.327% |
| PharmChem, Inc. | 1.05 Million USD | -264.107% |
| Proteome Sciences plc | -1.13 Million USD | 437.467% |
| Response Genetics, Inc | -19.66 Million USD | 119.511% |
| Rennova Health, Inc. | -234.81 Thousand USD | 1734.052% |
| RushNet, Inc. | -614.85 Thousand USD | 724.053% |
| ScreenPro Security Inc. | -3.43 Million USD | 211.707% |
| Stella Diagnostics Inc. | -5.7 Million USD | 167.228% |
| StageZero Life Sciences Ltd. | -10.27 Million USD | 137.361% |
| Todos Medical Ltd. | -9.39 Million USD | 140.845% |